Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Japanese encephalitis vaccine - Shandong Hengye Biotech

Next Previous
Drug Profile

Japanese encephalitis vaccine - Shandong Hengye Biotech

Alternative Names: Vero cell-derived inactivated Japanese encephalitis vaccine - Shandong Hengye Biotech

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Hengye Biotech
  • Developer Jiangsu Provincial Center for Disease Control and Prevention; Shandong Hengye Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Japanese encephalitis

Most Recent Events

  • 20 Sep 2017 Phase-III development for Japanese encephalitis (In infants, Prevention) is ongoing in China (Parenteral) (Shandong Hengye Biotech website, September 2017)
  • 18 Jul 2017 Shandong Hengye Biotech announces intention to carry out production registration declaration of vaccine for Japanese encephalitis (In infants, Prevention) in China in 2018 (Shandong Hengye Biotech website, September 2017)
  • 01 Oct 2014 Phase-III clinical trials in Japanese encephalitis (In infants, Prevention) in China (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top